Medibact GuidesShop at Medibact

Stacking Module

Cartalax Stacking Module

Cartalax is sold as the cartilage-oriented Khavinson bioregulator, and it is the least-evidenced compound in a group that is already thinly evidenced — including on cartilage itself, where its record is two 2023 cell-culture studies and no animal or human joint study. Its stacking rationale is entirely thematic — connective tissue — and the honest comparison is against the repair compounds, which have far more behind them.

Cartalax Guide at MedibactCartalax calculatorPeptide Stacking Guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking Cartalax

  • Cartalax is the tripeptide Ala-Glu-Asp (AED, research code T-31) from the Khavinson framework — not the tetrapeptide AEDL it is commonly sold as; NCBI indexes 'cartalax' as a synonym of alanyl-glutamyl-aspartic acid.
  • It is marketed for cartilage, and its cartilage evidence is two 2023 cell-culture studies from the developing group (stem-cell chondrogenic markers and chondrocyte senescence, PMIDs 37782646 and 37356100); no animal or human study of a joint is indexed, and the rest of its eighteen records concern kidney, skin, marrow, thymus, bone and periodontal-ligament models.
  • Its evidence base is the thinnest of the bioregulators here, with essentially no independent human data.
  • If connective-tissue repair is the objective, BPC-157 and TB-500 have substantially more preclinical evidence behind them — worth weighing before choosing or combining.
  • No controlled trial has studied Cartalax combined with anything.

Combinations in detail

Joint & Tissue Repair

Cartalax + BPC-157 + TB-500
Why it is proposed
Combines the cartilage-oriented bioregulator with the canonical repair pairing on the premise that they address connective tissue differently.
What is reported in practice
Reported as separate vials; Cartalax follows the bioregulator short-course convention while the repair compounds do not.
Cautions specific to this combination
The schedule conventions conflict — a short bioregulator course inside a longer repair block. And Cartalax contributes the least-evidenced element.

Connective Matrix / Collagen

Cartalax + GHK-Cu
Why it is proposed
Cartilage-oriented bioregulation alongside copper-driven collagen and matrix synthesis.
What is reported in practice
Separate compounds; GHK-Cu's strongest evidence is topical.
Cautions specific to this combination
GHK-Cu adds cumulative copper exposure. Both compounds' injected-route evidence is weak.

Bioregulator Longevity

Cartalax + Epithalon
Why it is proposed
Two bioregulators from the same framework addressing different tissues.
What is reported in practice
Short courses.
Cautions specific to this combination
Same narrow literature twice over.

What to avoid, and why

  • Choosing Cartalax over better-evidenced repair compounds for a connective-tissue objective without recognising the evidence gap.
  • Mixing bioregulator short-course conventions with continuous repair protocols without deciding which schedule governs.
  • This compound belongs to the Khavinson 'peptide bioregulator' family, whose literature originates overwhelmingly from one laboratory and its Russian collaborators, and whose central proposed mechanism — short peptides binding DNA promoter regions directly to regulate transcription — is not a broadly accepted model in mainstream molecular biology. Any stack built on it inherits that uncertainty.

Related reading

The Peptide Stacking GuideAll stacking pages

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.